Goldman Sachs Group Inc Anebulo Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 11,600 shares of ANEB stock, worth $28,536. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,600
Previous 47,954
75.81%
Holding current value
$28,536
Previous $62,000
74.19%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ANEB
# of Institutions
20Shares Held
22.6MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA15.5MShares$38 Million18.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.04MShares$7.47 Million0.19% of portfolio
-
Mangrove Partners New York, NY2.53MShares$6.21 Million0.53% of portfolio
-
Morgan Stanley New York, NY399KShares$982,0780.0% of portfolio
-
Lvw Advisors, LLC350KShares$860,0570.06% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $63.1M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...